TAMASERV is dedicated to advancing scientific research through developing and providing cutting-edge tools around RNA modifications. Our expertise lies in epitransriptomic solutions for RNA-based applications, supporting biotech and academics in unlocking new frontiers in molecular biology. With a strong commitment to precision and efficiency, we collaborate with partners around the globe to enhance RNA research and therapeutic developments. Expanding our vision, we have recently launched an ambitious crop yield improvement project. Leveraging our RNA modification expertise we are taking a dive into agricultural productivity and resilience. Recent high-profile research suggests that specific RNA modifications can serve as molecular predictors of crop resilience and yield. By integrating these insights with advanced analytics, we aim to develop novel strategies for improving agricultural products, particularly in regions with changing climate conditions. Partner with us in shaping the next generation of biotechnological advancements through unlocking the potential of RNA Modifications.
Takara Bio Inc.
Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc., is committed to helping scientists break new ground with innovative technologies for the life sciences. Our extensive portfolio of reagents, instruments, and services supports advancements across many areas of research, development, frontline diagnostics, and clinical applications. Our parent company, Takara Bio Inc., is a leading provider of biotechnology equipment and reagents, and conducts research and development activities involving gene- and cell-based therapies. Together with its subsidiaries, Takara Bio Inc. is committed to preventing disease and improving the quality of life for all through the use of biotechnology.
Taiwan Pavilion
Taiwan is located in the center of the Asia-Pacific region, with abundant medical resources, and diverse clusters of information and communication, semiconductor, and biomedical industries. It is suitable for the investment in development of precision health industries such as high-end medical materials, AI computing, and big data analysis. Taiwan medical device manufacturers have developed actively medical research and technology and we hope to cooperate with local industries, so it will be easier to enter the supply chain of major international brands. Metal Industries Research & Development Centre (MIRDC), a non-profit organization from Taiwan and assists Taiwan government to cultivate and reinforce the medical device industry in Taiwan. We also develop medical device products and technologies in industries including dental and orthopedic implants, devices, medical imaging, minimally invasive surgery instrument, and healthcare. | The biomedical industry is one of the six core strategic industries in Taiwan. It is an important power for Taiwan to play the leading role in global economy. With rich experiences of research, development and manufacturing, Taiwan excels in high-tech fields, clinical trials and biologics production. Continuing R&D support from government has created highly skilled workforce to innovate and advance the industry. Besides, Taiwan’s strategic location and grown-up supply chain make it an ideal partner for worldwide collaboration. There are more than 60 exhibitors and institutions in the Taiwan Pavilion this year, covering new drug development, CRO, CDMO, agriculture biotechnology, medical devices, precision medicine and smart health fields. Come and Join us to shape the future of precision health for all ages through collaboration and innovation with Taiwan’s thriving biomedical industry! | The biomedical industry is an important power for Taiwan to play the leading role in global economy. With rich experiences of research, development and manufacturing, Taiwan excels in high-tech fields, clinical trials and biologics production. Continuing R&D support from government has created highly skilled workforce to innovate and advance the industry. Besides, Taiwan’s strategic location and grown-up supply chain make it an ideal partner for worldwide collaboration. There are more than 60 exhibitors and institutions in the Taiwan Pavilion this year, covering new drug development, CRO, CDMO, agriculture biotechnology, medical devices, precision medicine and smart health fields. Come and Join us to shape the future of precision health for all ages through collaboration and innovation with Taiwan’s thriving biomedical industry! | BPIPO is honored to lead Taiwan’s delegation, featuring around 40 prominent companies and organizations specializing in new drug development, CDMO, regenerative medicine, agricultural biotechnology, precision medicine, and smart health. We warmly invite you to visit the Taiwan Pavilion and explore opportunities for collaboration. At our pavilion, you’ll discover not only innovative business partnerships but also insights into Taiwan’s supportive biomedical policies and unique research ecosystem. Taiwan has dedicated decades of effort to fostering a thriving biomedical industry, supported jointly by government initiatives and private sector innovation. This collaborative environment has successfully driven cross-domain growth and positioned Taiwan as a global biotechnology hub.
TaiHao Medical Inc
Taihao Medical designs and develops AI medical software to help healthcare providers manage the increasing workloads. We focus on breast screening & diagnostic solution by utilizing ultrasound and LDCT AI solutions for lung disease. Our leading products include: 1.BR-FHUSTM Smart System (Free-Hand ABUS): AI for ultrasound breast screening 2.BR-ViewerTM for ABUS 3.BU-CADTM Decision Support: AI for ultrasound breast cancer diagnosis 4.Ti–LUNGTM Decision Support: AI for LDCT lung cancer screening & diagnosis Leading technology & expertise include: 1.Real-Time AI detects suspicious areas in Ultrasound images 2.Advisory Board include scientists & physicians in Taiwan, Japan, China, and USA We have received US FDA, Japan’s PMDA, Taiwan’s TFDA, China’s NMPA, and more than 10 patent licenses. We not only advocate our products to the world, integrate with AI marketplace, but also cooperate with government’s screening program, women breast centers, mammography clinics, insurance companies and ultrasound machine manufacturers. Taihao Medical’s shareholders include CDIB Capital Healthcare Ventures Limited, Japan ＣＥＳデカルト, Top Taiwan Venture Capital Co., Ltd. and CTBC Securities Venture Capital Co., Ltd., who are involved in our capital investing. We strive for integrating our AI products in different types of ultrasound devices. Furthermore, global market expansion has been one of our key landmarks for the past and upcoming years, supported by our strong technical team in related areas. They are highly professional and well experienced. “Early Detection, Early Treatment, Most Lives Saved” is Taihao’s Value Proposition. We aim to be one of the most successful AI Medical companies worldwide. Welcome to follow our Linkedin and notice our continuous milestone, the latest news, and employees’ life in Taihao Medical.
SynOligo Biotechnologies
Headquartered in Morrisville, NC, USA, Synoligo Biotechnologies is a Contract Research and Development Organization (CRDO) specialized in manufacturing complex and highly modified oligonucleotide for academic, biotech start-up and large pharmaceutical communities. Synoligo is a leading oligonucleotide manufacturing company providing high quality, cost-effective custom oligonucleotides at varying scales for research, diagnostic, and therapeutic applications.
SYFM Co Ltd
We are equipped with the newest facilities to produce all kind of required items to produce our own unique products. Not only OEM, we can assure that we are expert on manufacturing products by ODM system with many years of experience to accomplish various requests from our customers.
Swissray Customer Care LLC
Swissray US delivers complete diagnostic imaging solutions that help healthcare providers improve efficiency, accuracy, and patient experience. We supply, install, and service advanced imaging systems from leading manufacturers, backed by a nationwide network of skilled engineers. Our tailored service programs minimize downtime, extend equipment life, and streamline workflows, enabling facilities to operate at peak performance while maintaining high-quality care standard.
SWISS Pavilion
Switzerland at BIO 2025: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2025 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2025. Join us in shaping the future of global health – the Swiss way. | Switzerland at BIO 2026: Innovation, Collaboration, and Global Impact Welcome to the SWISS Pavilion at BIO International Convention 2026 – your gateway to one of the world’s most dynamic and resilient biotech ecosystems. Switzerland stands at the forefront of global biotechnology, driven by a unique blend of scientific excellence, international collaboration, and a deep commitment to innovation that benefits patients and partners worldwide. Switzerland’s biotech industry continues to demonstrate remarkable strength and adaptability. According to the Swiss Biotech Report 2025, the sector attracted CHF 2.5 billion in capital investment in 2024 – a 22% increase over the previous year – despite global economic headwinds. This growth reflects the confidence of international investors in Swiss innovation and the country’s ability to deliver breakthrough solutions in healthcare, diagnostics, and life sciences. With over 1,000 biotech companies and a dense network of academic institutions, research centers, and global pharma leaders, Switzerland offers a fertile environment for biotech innovation. The industry contributes significantly to the national economy, with life sciences accounting for over 50% of Swiss exports. This year’s Swiss Biotech Report emphasizes the importance of international collaboration. Four out of five biotech patents filed in Switzerland are the result of cross-border partnerships. Swiss companies are not only developing therapies for the local market – they are building global business cases, forming strategic alliances, and co-developing solutions that address some of the world’s most pressing health challenges. At the SWISS Pavilion, you’ll find a curated selection of Switzerland’s most promising biotech innovators – from agile startups and academic spin-offs to established scale-ups and research-driven SMEs. While each exhibitor brings a unique value proposition, together they represent the full spectrum of Swiss biotech excellence: – Next-generation therapeutics: From immuno-oncology to gene and cell therapies, Swiss companies are advancing novel treatment modalities with global potential. – Cutting-edge diagnostics: Precision medicine is a key focus, with technologies that enable earlier, more accurate, and personalized diagnosis. – Digital health and AI: Swiss innovators are integrating data science and machine learning into biotech workflows, accelerating discovery and improving patient outcomes. – Sustainable biomanufacturing: Several exhibitors are pioneering green biotech solutions and scalable production platforms. – Academic and regional clusters: The Pavilion also features representatives from Switzerland’s leading biotech hubs, including the Basel Area, the Greater Zurich Area, and Greater Geneva Bern area, showcasing the country’s decentralized yet interconnected innovation landscape. Why visit the SWISS Pavilion? – Meet high-potential partners: Engage with companies actively seeking international collaborations, licensing opportunities, and investment. – Explore innovation across the value chain: From early-stage research to clinical development and commercialization. – Experience Swiss quality and reliability: A hallmark of Swiss biotech is its commitment to scientific rigor, regulatory excellence, and long-term partnerships. Whether you’re looking for your next strategic partner, investment opportunity, or simply want to explore the future of biotech, the SWISS Pavilion is your destination at BIO 2026. Join us in shaping the future of global health – the Swiss way. | Swissenviro was founded in 2015 by Urs Heutschi. It is a small, privately-owned company and the organizer of the SWISS Pavilion at international trade fairs for environmental technologies. With more than 20 years of experience, the international fair work is our area of expertise and forms the core of our work. The aim is to support export-orientated Swiss Cleantech SME to find buyers and business partners in international markets by encouraging international networking and direct B2B contacts on trade fairs and other events. By participation in a Joint Swiss Booth, the “SWISS Pavillon”, we are bringing together Swiss SMEs with professional trade visitors – potential future buyers, partners or suppliers. If desired, we gladly accompany and support the SME further on its business project resulting from this first customer contact. We closely work together with relevant Swiss environmental associations such as Cleantech Alps, VSA and Energie-Cluster. For our SWISS Pavilions we are supported by the MPK from “Switzerland Global Enterprise” (S-GE) and the “Swiss Federal Office for the Environment” (FOEN).
SUZHOU NORAYSO PROBE
Suzhou Norayso Technology Co., Ltd. is a high-tech enterprise specializing in the research, development, and manufacturing of ultrasound transducers. With years of dedicated experience in the ultrasound field, we are committed to advancing our products through technological innovation. We have established a comprehensive product portfolio that integrates “Standard + High-end Interventional/Implantable + Customized” solutions. In transducer technology, we possess robust capabilities in both composite PZT and single crystal materials. This enables us to provide professional probe design and manufacturing services, effectively meeting the growing market demand for high-performance single crystal probes. Our standard probe range covers commonly used types such as 1D, 1.5D, M4D, Ultra-high Frequency, and Bi-plane probes. We also focus on key interventional probes including ICE, IVUS, TEE, LUS, and EUS. Additionally, we offer wearable ultrasound probes, RCA, and personalized customization solutions. Guided by continuous innovation and dedicated service, Norayso looks forward to building long-term collaborative partnerships with medical clients and institutions worldwide.